地衣活性化合物C11H12O5体外抗肿瘤作用
In Vitro Anticancer Effects of Lichen Bioactive Compound C11H12O5
-
摘要: 目的 研究地衣活性化合物C11H12O5对人乳腺癌细胞株MCF-7、人肝癌细胞株HepG2及人肺腺癌细胞株A-549的体外抗癌作用, 观察其体外抗癌的剂量-效应关系和时间-效应关系.方法 采用体外细胞培养方式, 以MTT法检测OD值, 计算不同处理浓度和处理时间下肿瘤细胞的增殖抑制率.结果 化合物C11H12O5在剂量2、4、8、16和32μg/m L时, 对人乳腺癌细胞株MCF-7的抑制率分别为14.19%、13.84%、28.90%、59.50%、80.29%, IC50为12.43μg/m L;对人肝癌细胞株HepG2的抑制率分别为3.89%、11.09%、21.66%、46.27%、66.69%, IC50为18.88μg/m L;人肺腺癌细胞株A-549的抑制率分别为14.13%、11.09%、45.98%、86.19%、99.02%, IC50为6.21μg/m L.结论 地衣活性化合物C11H12O5对人乳腺癌细胞株MCF-7、人肝癌细胞株HepG2、人肺腺癌细胞株A-549均有显著体外抗肿瘤作用, 存在明显的剂量-效应关系, 其中A-549对该化合物最敏感.对A-549体外抑制作用时间-效应关系不明显.Abstract: Objectives To investigate the in vitro anticancer effects of lichen bioactive compound C11H12O5 on human breast cancer cell line MCF-7, human hepatoma cell line HepG2, human lung adenocarcinoma cell line A-549, and observe the dose-effect and time-effect.Methods MTT assay was used in the in vitro anticancer study.The OD values at 24 h, 48 h, 72 h were examined and the inhibitory ratios were calculated.Results The inhibitory ratios were 14.19%, 13.84%, 28.90%, 59.50%, 80.29% in MCF-7;3.89%, 11.09%, 21.66%, 46.27% and 66.69% in HepG2 and 14.13%, 11.09%, 45.98%, 86.19%, 99.02% in A-549 at 2, 4, 8, 16, 32 μg/m L of compound C11H12O5.The IC50 were 12.43 μg/m L, 18.88 μg/m L and 6.21 μg/m L in MCF-7, HepG2 and A-549 respectively.Conclusions Compound C11H12O5 has significant in vitro anticancer effects on MCF-7, HepG2, A-549.The anticancer effects is dose dependent.A-549 is the most sensitive cell line.The timeeffect of the in vitro anticancer effect in A-549 is not evident.
-
[1]王春华, 姜苗苗, 王国才, 等.从中药及天然药物中寻找肿瘤多药耐药逆转剂的研究进展[J].国际药学研究杂志, 2013, 40 (6) :678-687.[1]王春华, 姜苗苗, 王国才, 等.从中药及天然药物中寻找肿瘤多药耐药逆转剂的研究进展[J].国际药学研究杂志, 2013, 40 (6) :678-687. [2] [2]CHEN W, ZHENG R, ZENG H, et al.Annual report on status of cancer in China, 2011[J].Chin J Cancer Res, 2015, 27 (1) :2-12.[2]CHEN W, ZHENG R, ZENG H, et al.Annual report on status of cancer in China, 2011[J].Chin J Cancer Res, 2015, 27 (1) :2-12. [3]陈肖肖.中药有效成分提取分离技术研究进展[J].临床合理用药, 2013, 6 (6) :178-180.[3]陈肖肖.中药有效成分提取分离技术研究进展[J].临床合理用药, 2013, 6 (6) :178-180. [4]陈万青, 郑荣寿, 张思维.中国恶性肿瘤的动态变化[J].科技导报, 2014, 32 (26) :65-71.[4]陈万青, 郑荣寿, 张思维.中国恶性肿瘤的动态变化[J].科技导报, 2014, 32 (26) :65-71. [5]吴菲, 林国祯, 张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤, 2012, 21 (2) :81-85.[5]吴菲, 林国祯, 张晋昕.我国恶性肿瘤发病现状及趋势[J].中国肿瘤, 2012, 21 (2) :81-85. [6]肖绍文, 张珊文.肿瘤放射治疗临床进展[J].科技导报, 2014, 32 (26) :37-41.[6]肖绍文, 张珊文.肿瘤放射治疗临床进展[J].科技导报, 2014, 32 (26) :37-41. [7]王世昌, 陈朝.活血通痹方联合甲钴胺注射液治疗胃肠肿瘤化疗致周围神经病变的疗效观察[J].中国实用神经疾病杂志, 2014, 17 (7) :96-97.[7]王世昌, 陈朝.活血通痹方联合甲钴胺注射液治疗胃肠肿瘤化疗致周围神经病变的疗效观察[J].中国实用神经疾病杂志, 2014, 17 (7) :96-97. [8]闫长会.铂类抗肿瘤药体外肾毒性的比较研究[D].北京:军事医学科学院毒物药物研究所, 2004.[8]闫长会.铂类抗肿瘤药体外肾毒性的比较研究[D].北京:军事医学科学院毒物药物研究所, 2004. [9]吴秀兰, 贾艳, 朱波, 等.天然抗癌药物紫杉醇的研究进展[J].中国野生植物资源, 2014, 33 (5) :42-45.[9]吴秀兰, 贾艳, 朱波, 等.天然抗癌药物紫杉醇的研究进展[J].中国野生植物资源, 2014, 33 (5) :42-45. [10] [10]ARRONDEAU J, GAN H K, RAZAK A R, et al.Development of anti-cancer drugs[J].Discov Med, 2010, 10 (53) :355-362.[10]ARRONDEAU J, GAN H K, RAZAK A R, et al.Development of anti-cancer drugs[J].Discov Med, 2010, 10 (53) :355-362. [11] [11]DOERING M, BA LA, LILIENTHAL N, et al.Synthesis and selective anticancer activity of organochalcogen based redox catalysts[J].J Med Chem, 2010, 53 (19) :6954-6963.[11]DOERING M, BA LA, LILIENTHAL N, et al.Synthesis and selective anticancer activity of organochalcogen based redox catalysts[J].J Med Chem, 2010, 53 (19) :6954-6963. [12] [12]LEE K H.Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach[J].J Nat Prod 2010, 73 (3) :500-516.[12]LEE K H.Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach[J].J Nat Prod 2010, 73 (3) :500-516. [13]贺小琼.天然植物制剂AMH体外抑制多种强效致癌物的致突变作用[J].肿瘤, 2003, 23 (6) :494-496.[13]贺小琼.天然植物制剂AMH体外抑制多种强效致癌物的致突变作用[J].肿瘤, 2003, 23 (6) :494-496. [14]贺小琼, 李凝诗, 李凤, 等.真菌提取物AMH的肿瘤化学预防活性组分追踪[J].癌变、畸变, 突变, 2011, 23 (3) :166-169.[14]贺小琼, 李凝诗, 李凤, 等.真菌提取物AMH的肿瘤化学预防活性组分追踪[J].癌变、畸变, 突变, 2011, 23 (3) :166-169. [15] [15]XIAOQIONG H E.The antimutagenicity and anticancer effectsof a kind of wild mushroom extract[C].Proceedingsof the American Association for Cancer Research, 2007.[15]XIAOQIONG H E.The antimutagenicity and anticancer effectsof a kind of wild mushroom extract[C].Proceedingsof the American Association for Cancer Research, 2007. [16]贺云发, 贺小琼, 姜重阳, 等.地衣抗癌活性部位AMH-T的毒理学研究[J].昆明医科大学学报, 2014, 37 (11) :1-4.[16]贺云发, 贺小琼, 姜重阳, 等.地衣抗癌活性部位AMH-T的毒理学研究[J].昆明医科大学学报, 2014, 37 (11) :1-4. [17]李银燕, 王秀君.铂类抗癌药物作用靶点及耐药机制的研究进展[J].中国细胞生物学学报, 2013, 35 (7) :1011-1012.[17]李银燕, 王秀君.铂类抗癌药物作用靶点及耐药机制的研究进展[J].中国细胞生物学学报, 2013, 35 (7) :1011-1012. [18] [18]THOMAS BOY LE F, COSTELLO G F.Cancer therapy:a move to the molecular level[J].Chem Soc Rev, 1998, 27 (1) :251-261.[18]THOMAS BOY LE F, COSTELLO G F.Cancer therapy:a move to the molecular level[J].Chem Soc Rev, 1998, 27 (1) :251-261. [19]刘晓霓, 谢棒祥, 谢立, 等.应用基因芯片技术研究抗肿瘤传统和天然药物相关文献[J].世界科学技术-中医药现代化思路与方法, 2014, 16 (12) :2522-2525.[19]刘晓霓, 谢棒祥, 谢立, 等.应用基因芯片技术研究抗肿瘤传统和天然药物相关文献[J].世界科学技术-中医药现代化思路与方法, 2014, 16 (12) :2522-2525. [20]刘怀泽, 俞婷婷, 程雁.PIAS1通过调控Sonic hedgehog信号通路使胰腺癌细胞SW1990获得对吉西他滨的耐药性[J].南京医科大学学报 (自然科学版) , 2016, 36 (7) :769-773.[20]刘怀泽, 俞婷婷, 程雁.PIAS1通过调控Sonic hedgehog信号通路使胰腺癌细胞SW1990获得对吉西他滨的耐药性[J].南京医科大学学报 (自然科学版) , 2016, 36 (7) :769-773.
点击查看大图
计量
- 文章访问数: 2450
- HTML全文浏览量: 960
- PDF下载量: 92
- 被引次数: 0